Taro Takahara, MD, PhD, is a board-certified radiologist and MRI researcher specializing in diffusion-weighted imaging and whole-body MRI. In 2004, he developed DWIBS (Diffusion-weighted Whole-body Imaging with Background Body Signal Suppression), a whole-body diffusion-weighted MRI technique that contributed to the advancement of MRI-based cancer screening. This work has been cited more than 1,300 times according to Google Scholar.
His major research interests include whole-body MRI, oncologic imaging, diffusion-weighted MRI, and MR neurography. His work on MR neurography was featured on the cover of Radiology, and he also reported whole-body MR neurography in the New England Journal of Medicine (NEJM).
He has actively promoted non-contrast MRI-based cancer screening and has continued research on the utility of DWIBS in stereotactic body radiotherapy for oligometastatic prostate cancer and other oncologic imaging applications.
From 2007 to 2010, he served as a Visiting Associate Professor at Utrecht University in the Netherlands. Until 2025, he was Professor in the Department of Biomedical Engineering at Tokai University. He is currently Clinical Professor at Institute of Science Tokyo (formerly Tokyo Medical and Dental University), Tokyo, Japan.
Taro Takahara, MD, PhD, is a board-certified radiologist and MRI researcher specializing in diffusion-weighted imaging and whole-body MRI. In 2004, he developed DWIBS (Diffusion-weighted Whole-body Imaging with Background Body Signal Suppression), a whole-body diffusion-weighted MRI technique that contributed to the advancement of MRI-based cancer screening. This work has been cited more than 1,300 times according to Google Scholar.
His major research interests include whole-body MRI, oncologic imaging, diffusion-weighted MRI, and MR neurography. His work on MR neurography was featured on the cover of Radiology, and he also reported whole-body MR neurography in the New England Journal of Medicine (NEJM).
He has actively promoted non-contrast MRI-based cancer screening and has continued research on the utility of DWIBS in stereotactic body radiotherapy for oligometastatic prostate cancer and other oncologic imaging applications.
From 2007 to 2010, he served as a Visiting Associate Professor at Utrecht University in the Netherlands. Until 2025, he was Professor in the Department of Biomedical Engineering at Tokai University. He is currently Clinical Professor at Institute of Science Tokyo (formerly Tokyo Medical and Dental University), Tokyo, Japan.